Trial Profile
Actinium-225 (225Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2019
Price :
$35
*
At a glance
- Drugs Lintuzumab Ac-225 (Primary) ; Plerixafor; Spironolactone
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 26 Mar 2019 According to an Actinium Pharmaceuticals media release, data from this study will be presented at the 11th Targeted-Alpha-Therapy International Symposium (TAT) (Apr 2019).
- 04 Dec 2018 Preliminary data of the interim analysis (n=18) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 03 Dec 2018 Results from the second cohort of the patients (n=27) presented in a media release.